biotechnolog
innov
gain
increas
recognit
import
tool
improv
global
health
challeng
howev
lie
defin
role
technolog
transfer
develop
therapi
diseas
preval
develop
countri
past
decad
larg
dispar
emerg
develop
develop
world
access
afford
medicin
pharmaceut
industri
focu
health
area
bear
greatest
profit
discuss
herein
sever
mechan
provid
partial
solut
challeng
offic
technolog
transfer
us
nation
institut
health
increas
technolog
licens
pertain
neglect
diseas
partner
develop
region
establish
partnership
transfer
technolog
assist
indigen
institut
build
r
capac
may
posit
impact
polici
protect
intellectu
properti
right
increas
multin
compani
invest
lesserdevelop
countri
probabl
result
develop
access
therapi
need
publish
elsevi
inc
mission
us
nation
institut
health
nih
depart
health
human
servic
support
biomed
research
extend
healthi
life
reduc
ill
worldwid
part
effort
nih
seek
understand
challeng
hinder
public
avail
invent
made
nih
scientist
articl
review
result
initi
effort
narrow
gap
particularli
develop
countri
possibl
global
benefit
nih
invent
especi
area
pertain
biotechnolog
nih
offic
technolog
transfer
ott
lead
offic
manag
patent
licens
invent
made
scientist
nih
food
drug
administr
fda
ott
activ
explor
way
improv
technolog
transfer
develop
countri
particularli
identifi
biomed
research
institut
foundat
compani
latin
america
africa
asia
transit
economi
eastern
europ
field
biotechnolog
long
subject
intellectu
properti
right
ipr
domin
multin
western
compani
continu
adapt
chang
global
econom
climat
organ
econom
cooper
develop
oecd
scienc
health
minist
conclud
last
annual
report
biotechnolog
key
driver
sustain
growth
develop
oecd
member
countri
beyond
oecd
report
today
develop
nation
enorm
human
capit
like
india
china
brazil
korea
abl
demonstr
capabl
accomplish
sever
biotechnolog
r
activ
mani
other
countri
like
mexico
argentina
chile
south
africa
egypt
thailand
hungari
czech
republ
readi
eager
follow
exampl
howev
road
ahead
prove
difficult
one
develop
nation
support
develop
therapi
product
endem
neglect
diseas
requir
build
sustain
infrastructur
nation
mani
countri
typic
prerequisit
element
welleduc
train
popul
scientif
excel
businessfriendli
set
intellectu
properti
right
regulatori
infrastructur
healthcar
system
simpli
suffici
absent
marshal
lack
essenti
build
block
present
enorm
hurdl
nascent
biotechnolog
industri
develop
countri
industri
nation
intern
organ
oblig
encourag
innov
form
new
collabor
allianc
institut
develop
countri
provid
sustain
guidanc
resourc
build
capabl
biotechnolog
infrastructur
urgent
need
mani
expert
agre
famili
access
medicin
feel
confid
children
live
longer
overal
standard
live
develop
countri
rise
result
econom
expans
reduc
global
popul
growth
savedoff
schultz
daar
et
al
unfortun
medicin
develop
multin
compani
expens
individu
develop
nation
must
pay
medicin
pocket
afford
exampl
aid
drug
cocktail
patent
holder
charg
us
annual
certain
market
howev
absenc
patent
regul
maker
gener
drug
sell
version
less
us
boulet
et
al
even
less
expens
drug
may
still
inaccess
extrem
poor
mani
develop
countri
unabl
compet
afford
competitor
product
focus
biotechnolog
impetu
produc
afford
therapeut
altern
instead
support
novel
drug
innov
larg
possibl
lenient
patent
regul
thorsteinsdotir
et
al
india
world
leader
gener
drug
manufactur
prime
exampl
reduc
cost
product
way
make
medicin
afford
underprivileg
individu
kumar
et
al
mani
countri
enter
new
phase
biotechnolog
develop
nih
ott
recogn
need
transfer
biotechnolog
intern
thu
encourag
institut
region
practic
innov
entrepreneurship
matur
biotechnolog
health
sector
develop
nation
researchintens
expens
compli
evermor
stringent
ipr
system
ott
therefor
feel
compel
extend
mission
nih
cultiv
publicpriv
partnership
beyond
border
us
work
institut
intern
organ
privat
foundat
ott
identifi
urgent
technolog
transfer
tt
need
opportun
relat
hivaid
pertussi
malaria
dengu
childhood
diarrhea
rotaviru
mening
typhoid
fever
cancer
diabet
ott
alreadi
transfer
technolog
current
negoti
licens
public
privat
institut
india
mexico
brazil
china
korea
egypt
south
africa
experi
demonstr
government
notforprofit
research
institut
transfer
earli
stage
biomed
technolog
institut
pharmaceut
compani
western
world
cours
done
haphazardli
nih
ott
learn
key
lesson
expand
licens
activ
develop
countri
particip
institut
research
develop
r
capabl
clear
nation
region
public
health
object
two
condit
met
access
key
technolog
model
success
product
develop
nih
enhanc
prevent
care
infecti
noncommunic
diseas
encourag
technolog
transfer
nih
contribut
longterm
global
mission
reduc
burden
diseas
particularli
devast
peopl
live
develop
countri
nih
ott
also
recogn
relev
assist
develop
cadr
scientist
technolog
manag
experienc
intellectu
properti
manag
ipm
technolog
transferrel
matter
overcom
obstacl
necessarili
longterm
project
also
eventu
selfsustain
one
first
step
ott
work
partnership
stakehold
develop
countri
us
europ
assess
technolog
transfer
train
need
institut
develop
countri
moreov
ott
also
initi
intern
technolog
transfer
capac
build
program
train
scientist
manag
develop
countri
first
phase
includ
train
staff
institut
china
brazil
india
futur
expans
program
envis
relev
personnel
african
latin
american
asian
european
institut
nih
domest
agenc
one
might
natur
ask
question
nih
involv
intern
technolog
transfer
nih
risk
leak
knowledg
might
put
unit
state
competit
disadvantag
strong
case
enhanc
technolog
transfer
develop
countri
would
allow
develop
technolog
appropri
region
need
enabl
local
region
solut
public
health
need
oecd
varmu
et
al
saha
et
al
nih
mission
extend
beyond
border
unit
state
reason
reflect
statement
bscienc
pursuit
fundament
knowledg
natur
behavior
live
system
applic
knowledg
extend
healthi
life
reduc
burden
ill
disabilityq
nih
commit
achiev
mission
foster
fundament
creativ
discoveri
innov
research
strategi
applic
basi
advanc
significantli
nation
capac
protect
improv
health
develop
maintain
renew
scientif
human
physic
resourc
assur
nation
capabl
prevent
diseas
addit
address
critic
challeng
global
health
bill
melinda
gate
foundat
grant
million
foundat
nation
institut
health
fnih
manag
grand
challeng
global
health
initi
support
increas
research
diseas
caus
million
death
third
world
countri
furthermor
one
nih
goal
technolog
transfer
specif
bstrengthen
capac
develop
countri
identifi
technolog
pursu
develop
product
educ
technic
assistanceq
extend
r
activ
outsid
us
border
transfer
technolog
knowhow
develop
countri
learnbydo
gain
technolog
capabl
marshal
facilit
develop
technolog
capabl
partner
better
leverag
valu
technolog
extend
scientif
knowledg
practic
overal
activ
like
add
valu
provid
social
return
exist
invent
gardner
garner
social
return
realiz
public
sector
vast
financi
invest
biomed
r
either
directli
serv
us
market
indirectli
improv
health
peopl
worldwid
prevent
spread
diseas
across
us
border
number
studi
document
exist
major
global
health
dispar
greatest
burden
born
develop
countri
gwatkin
guillot
tdr
report
one
primari
reason
lack
access
advanc
technolog
address
emerg
reemerg
noncommunic
diseas
major
part
develop
world
also
well
known
problem
persist
larg
incent
develop
world
provid
technolog
solut
eg
drug
vaccin
diagnost
problem
trouiller
et
al
fig
illustr
potenti
impact
biotechnolog
innov
global
heath
new
solut
develop
treatment
rare
diseas
found
poor
nation
may
come
opensourc
research
practic
biotechnolog
approach
may
foster
biomed
innov
significantli
reduc
r
expenditur
often
pose
barrier
justifi
new
drug
develop
combat
mani
neglect
diseas
advantag
recent
exemplifi
human
genom
project
initi
place
relev
scientif
data
resourc
public
domain
without
allow
one
entiti
hold
patent
invent
much
need
cure
tropic
diseas
develop
approach
maurer
et
al
similarli
variou
type
patent
pool
arrang
particular
technolog
could
provid
relief
challeng
ip
fragment
present
stifl
biomed
develop
thu
access
essenti
medicin
exampl
develop
technolog
intervent
sever
acut
respiratori
syndrom
sar
could
expedit
licens
cost
reduc
cooper
pool
sarsrel
patent
rimmer
creation
winwin
situat
ip
holder
vaccin
manufactur
popul
need
gain
increas
consider
among
preval
caus
death
develop
countri
communic
diseas
like
hiv
aid
tuberculosi
malaria
claim
million
death
annual
mortal
result
malnutrit
contamin
water
overal
poor
sanit
even
greater
exampl
neglect
diseas
plagu
mani
african
nation
receiv
littl
attent
politician
forprofit
corpor
invest
provid
treatment
lymphat
filariasi
elephantiasi
schistosomiasi
intestin
parasit
leprosi
sleep
sick
african
trypanosomiasi
leishmaniasi
trouiller
et
al
report
program
appli
ethic
biotechnolog
paeb
canadian
program
genom
global
health
cpggh
univers
toronto
joint
center
bioethic
develop
report
top
biotechnolog
improv
health
develop
countri
report
list
molecular
diagnost
recombin
vaccin
vaccin
drug
deliveri
bioremedi
enrich
gm
crop
among
promis
biotechnolog
improv
global
health
daar
et
al
report
warn
possibl
bgenom
divideq
littl
biotechnolog
focus
health
problem
preval
develop
nation
genet
cost
r
new
drug
estim
million
includ
opportun
cost
absorb
cost
failur
kettler
di
masi
et
al
instanc
nearli
new
drug
regist
drug
tropic
diseas
olliaro
trouiller
dndi
work
group
msf
howev
annual
million
death
worldwid
infecti
communic
diseas
occur
develop
countri
oecd
advanc
dramat
improv
health
develop
countri
equal
benefit
poor
one
ott
primari
mission
accomplish
goal
set
nih
establish
new
line
commun
institut
develop
countri
scope
research
conduct
nih
institut
includ
investig
diseas
enorm
health
burden
develop
countri
fruit
patent
invent
born
research
meant
benefit
sole
privileg
bring
profit
pharmaceut
industri
boulet
et
al
public
health
institut
public
health
servic
ph
nih
mission
includ
make
biomed
invent
avail
need
incent
ott
engag
intern
activ
contribut
reduct
burden
diseas
global
mani
develop
countri
stand
benefit
licens
nih
invent
develop
technolog
local
price
afford
underprivileg
popul
transfer
technolog
may
play
particularli
import
role
turn
earlystag
technolog
useabl
product
third
world
countri
importantli
enabl
indigen
institut
develop
nih
technolog
region
local
capac
research
develop
market
competit
experienc
work
forc
scientif
excel
improv
biotechnolog
infrastructur
grow
consequ
ultim
help
strengthen
stabil
develop
countri
economi
mani
success
activ
particip
develop
countri
r
activ
meet
local
need
alreadi
exist
product
hepat
b
vaccin
multipl
indian
compani
kumar
et
al
recombin
human
insulin
vaccin
develop
produc
brazil
meet
popul
need
ferrer
et
al
egypt
advanc
agbiotechnolog
field
aim
meet
acut
insulin
shortag
local
develop
recombin
human
insulin
abdelgafar
et
al
global
dissemin
diseas
across
contin
rapid
migrat
human
popul
dynam
pose
new
challeng
unit
state
inde
wide
recogn
intern
commun
diseas
contain
within
region
border
threaten
unit
state
two
way
emerg
reemerg
infecti
diseas
epidem
increas
movement
good
anim
peopl
diseas
spread
rapidli
across
border
pose
direct
threat
us
citizen
suffic
mention
epidem
diseas
hivaid
influenza
tuberculosi
cholera
sar
certain
part
world
threaten
region
origin
also
entir
globe
global
health
council
wwwglobalhealthorg
risk
terror
access
drug
medic
technolog
genuin
public
welfar
concern
mani
develop
countri
hirschberg
et
al
inde
spread
diseas
often
fuel
poverti
suffer
civil
disord
provid
access
need
medic
technolog
reduc
burden
diseas
improv
qualiti
life
volatil
area
globe
diminish
unrest
fuel
terror
despit
great
need
pharmaceut
firm
incent
invest
product
treat
prevent
diseas
primarili
afflict
poor
countri
low
return
invest
highrisk
costli
biomed
r
trouiller
et
al
clearli
illustr
tuberculosi
new
gener
drug
reach
market
thirti
year
larg
diseas
ceas
prioriti
wealthi
nation
whose
abil
pay
high
price
drug
enabl
compani
recoup
steep
invest
tb
allianc
medicin
san
bdoctor
without
bordersq
estim
last
thirti
year
new
drug
develop
tropic
diseas
new
drug
develop
cardiovascular
diseas
alon
thorsteinsdotir
et
al
similar
challeng
also
exist
vaccin
develop
pandem
diseas
introduct
product
develop
world
market
delay
significantli
exampl
effect
vaccin
measl
use
west
past
forti
year
develop
world
gain
limit
access
vaccin
recent
whounicef
addit
financi
logist
challeng
intern
effort
socal
gap
meant
world
drug
reach
popul
kettler
olliaro
trouiller
health
forum
health
research
held
mexico
citi
novemb
set
intensifi
complet
millennium
develop
goal
mdg
collabor
multin
partner
close
gap
health
research
need
develop
countri
global
forum
health
research
meet
statement
remot
casesthos
acut
threat
pose
unit
statesthat
except
made
vaccin
therapeut
produc
govern
subsidi
provid
antiretrovir
drug
develop
countri
well
known
case
malaria
diseas
virtual
erad
use
insecticid
malaria
drug
north
america
europ
iron
practic
led
increasingli
resist
mosquito
vector
africa
asia
latin
america
effort
made
toward
develop
malaria
vaccin
malaria
repres
low
prioriti
health
risk
develop
nation
situat
lead
bill
melinda
gate
foundat
launch
support
malaria
vaccin
initi
mvi
effort
address
seriou
shortcom
acceler
vaccin
develop
combat
diseas
affect
million
peopl
round
world
mvi
consequ
rel
technolog
advanc
develop
countri
enhanc
r
capac
expertis
product
commerci
meet
local
need
includ
develop
andor
enhanc
appropri
capac
lessdevelop
countri
enabl
academ
research
institut
benefit
sustain
way
invest
salicrup
et
al
sever
research
studi
indic
best
approach
combat
longterm
neglect
diseas
poor
countri
subsaharan
africa
part
asia
latin
america
caribbean
eastern
europ
boulet
et
al
inde
recent
work
wellrespect
privat
foundat
gate
rockefel
foundat
policymak
emphas
develop
countri
bneed
selfreli
nation
product
healthbiotechnolog
ensur
countryspecif
diseas
need
metq
saha
et
al
thorsteinsdotir
et
al
maurer
et
al
world
intellectu
properti
organ
wipo
cooper
develop
program
commit
tailor
activ
implement
ip
strategi
divers
infrastructur
need
develop
countri
wipo
similarli
organ
econom
cooper
develop
oecd
state
strongli
bthe
transfer
technolog
develop
countri
key
element
countri
develop
r
infrastructur
capabl
meet
needsq
oecd
develop
countri
reach
certain
level
technolog
capac
encourag
foster
dynam
capabl
nurtur
domest
asset
creativ
blend
domest
foreign
knowledg
marshal
polici
recommend
support
extens
research
show
innov
capabl
intern
technolog
transfer
key
element
maintain
expand
nation
share
global
economi
romer
ariffin
bell
boulet
et
al
technolog
transfer
refer
bani
process
one
parti
gain
access
anoth
technic
inform
success
learn
absorb
product
processq
masku
facilit
research
develop
transfer
ensur
wide
applic
scientif
discoveri
method
procedur
techniqu
equip
promot
health
econom
develop
nih
use
varieti
mechan
facilit
transfer
patent
licens
invent
scientif
public
share
knowledg
transfer
uniqu
biolog
materi
scientif
collabor
basic
appli
research
major
channel
licens
patentpend
patent
invent
btypic
involv
purchas
product
distribut
right
underli
technic
inform
knowhowq
masku
patent
directli
facilit
kind
knowledg
transfer
biotechnolog
innov
power
effect
tool
worldwid
reduct
poverti
difficulti
manag
vast
health
burden
mere
question
scienc
also
economi
infrastructur
tdr
maurer
et
al
posit
side
effect
increas
biotechnolog
transfer
develop
countri
reduc
spread
impact
diseas
improv
socioeconom
stand
impoverish
popul
cmh
report
organ
econom
cooper
develop
oecd
bconfer
biotechnolog
infecti
diseas
address
global
need
oecd
q
strongli
recommend
view
clearli
articul
bthe
transfer
technolog
develop
countri
key
element
countri
develop
r
infrastructur
capabl
meet
needsq
bgrand
challeng
global
health
q
varmu
et
al
panel
analyz
bgrand
challengesq
suggest
seven
overarch
goal
challeng
relat
develop
new
better
technolog
effect
vaccin
technolog
effici
vaccin
drugdeliveri
system
diagnost
tool
therapeut
bioavail
nutrit
system
via
genet
modif
plant
etc
view
reiter
dr
elia
zerhouni
former
director
nation
cancer
institut
varmu
et
al
furthermor
one
key
messag
world
leader
world
summit
sustain
develop
wssd
held
johannesburg
south
africa
need
build
capac
scienc
technolog
enterpris
develop
world
sustain
approxim
one
third
world
popul
btechnolog
depriv
q
global
popul
provid
almost
technolog
innov
juma
et
al
global
forum
health
research
clearli
imbal
need
address
collabor
countri
across
sector
technolog
area
outsid
nation
core
compet
one
way
reduc
inequ
enabl
transfer
technolog
knowledg
applic
underinvest
area
crucial
act
quickli
transfer
relev
expertis
scientif
knowledg
develop
countri
institut
transform
healthrel
product
area
neglect
develop
countri
innov
nih
recogn
potenti
benefit
glean
particip
intern
technolog
transfer
also
acut
awar
potenti
loss
absenc
particularli
develop
countri
dire
need
technolog
shortfal
see
masku
concis
review
area
offic
respons
patent
licens
invent
made
scientist
nih
fda
ott
activ
explor
way
improv
process
transfer
public
health
servic
ph
technolog
develop
countri
particular
ott
identifi
biomed
research
institut
foundat
compani
asia
latin
america
africa
eastern
europ
interest
capac
receiv
develop
new
technolog
collabor
differ
partner
ott
identifi
urgent
technolog
transfer
need
opportun
relat
hiv
aid
malaria
pertussi
dengu
childhood
diarrhea
rotaviru
mening
chickenpox
cancer
diabet
ott
alreadi
transfer
technolog
current
negoti
licens
begin
transfer
institut
india
mexico
brazil
argentina
china
korea
egypt
south
africa
one
goal
nih
ott
address
avail
gap
ph
invent
make
technolog
access
peopl
around
world
leadership
biomed
research
innov
well
manag
technolog
commerci
across
sector
us
prime
posit
lead
help
countri
formul
appropri
technologytransf
procedur
develop
world
leader
biomed
research
nih
ott
play
signific
role
intern
technolog
transfer
zerhouni
larg
portfolio
year
experi
technolog
transfer
nih
ott
also
well
posit
move
technolog
privat
sector
commerci
us
abroad
total
execut
licens
licens
amend
licens
execut
foreign
entiti
date
fy
foreign
licens
new
amend
execut
total
new
licens
amend
even
opportun
intern
technolog
transfer
develop
countri
china
india
brazil
south
africa
becom
emerg
economi
expertis
advanc
technolog
biomed
r
capabl
nih
forefront
endeavor
made
technolog
access
public
manag
intellectu
properti
patent
licens
technolog
put
use
approxim
market
product
servic
part
collabor
govern
privat
industri
academia
intern
organ
privat
foundat
includ
hivab
aid
test
kitkabbott
other
videxk
ddibm
taxolk
paclitaxelbm
fludarak
fludarabinesch
havrixk
hepat
vaccinegsk
synagisk
monoclon
antibodi
respiratori
syncyti
viru
rsv
medimmun
nih
alreadi
develop
rel
strong
portfolio
neglect
infecti
diseas
shown
tabl
technolog
yet
fulli
exploit
note
may
technolog
market
diseas
may
either
obsolet
inaccess
developingcountri
market
due
cost
involv
complic
deliveri
mechan
continu
hamper
effort
turn
earlystag
technolog
useabl
product
eg
iipi
http
wwwiipiorgactivitiesprojectstechtransferhtm
inde
approxim
activ
nih
licens
execut
institut
outsid
us
hoekman
et
al
cipr
ernst
young
rivett
kline
falconi
salazar
juma
clark
iipi
http
wwwiipiorg
activitiesprojectstechtransferhtm
ott
alreadi
success
move
ph
technolog
institut
develop
countri
india
brazil
base
publichealth
need
r
commerci
capabl
institut
even
fewer
countri
familiar
patent
licens
process
andor
abl
enter
wellprepar
technolog
transfer
transact
negoti
term
condit
ipr
consid
critic
currenc
technolog
transfer
innov
gener
intellectu
properti
right
implic
develop
ictsd
unctad
technolog
worldwid
market
relat
hivaid
tuberculosi
nih
ott
adopt
licens
term
last
year
requir
compani
north
america
europ
provid
market
plan
make
product
avail
develop
countri
usual
plan
due
shortli
receiv
first
market
approv
sinc
technolog
earli
stage
none
licens
govern
term
yet
reach
mileston
licens
technolog
directli
compani
develop
countri
often
involv
agreement
enforc
benchmark
track
license
progress
addit
benchmark
may
link
public
health
polici
stipul
safe
clinic
trial
environmentconsci
practic
nih
ott
continu
explor
way
enhanc
transfer
technolog
institut
develop
countri
drive
market
technolog
parti
interest
enter
developingcountri
market
contact
develop
worldwid
r
institut
develop
countri
privat
public
sector
ott
proactiv
search
potenti
partner
develop
countri
key
neglect
diseas
includ
communic
ie
hivaid
dengu
rotaviru
noncommunic
diseas
ie
cancer
diabet
commerci
licens
involv
transfer
right
util
intellectu
properti
well
uniqu
materi
case
nih
ott
util
type
licens
incent
develop
product
develop
world
intellectu
properti
right
enforc
countri
patent
technolog
use
manufactur
product
countri
product
sold
thu
countri
patent
owner
sought
patent
protect
often
case
mani
develop
countri
biolog
materi
licens
agreement
import
incent
provid
institut
level
market
protect
transfer
technolog
addit
nih
ott
util
geograph
exclus
coexclus
incent
license
develop
biotechnologyrel
product
particular
region
market
exclus
licens
need
encourag
commerci
nonexclus
licens
region
worldwid
allow
multipl
parti
compet
market
develop
product
anticip
licens
strategi
might
major
impact
access
health
technolog
great
need
industri
develop
countri
frame
market
strategi
intern
product
develop
mechan
util
complex
way
provid
appropri
incent
countri
region
otherwis
licens
term
institut
serv
public
health
need
lessindustri
countri
would
compar
nih
ott
licens
institut
industri
countri
royalti
fee
negoti
case
case
basi
depend
factor
market
plan
market
size
potenti
use
public
interest
need
licens
addit
technolog
use
paradigm
allow
ott
fulfil
statutori
requir
favor
small
us
busi
us
market
use
exclus
licens
strategi
need
nih
increas
file
patent
import
vaccin
therapeut
countri
like
china
india
brazil
mexico
local
entiti
incent
develop
product
addit
nih
make
effort
transfer
knowhow
critic
document
manufactur
help
develop
countri
expedit
develop
effort
also
select
partner
countri
rigor
base
compani
scientif
commerci
capabl
biotechnolog
innov
subject
ip
right
decad
signific
human
health
care
field
well
potenti
biotechnolog
tool
reliev
burden
diseas
worldwid
also
grown
ongo
analysi
portfolio
need
capabl
develop
countri
ott
found
nich
exist
technolog
transfer
jeopard
us
technolog
public
health
econom
interest
transfer
moreov
provid
solut
socioeconom
harm
diseas
ott
alreadi
transfer
earlystag
technolog
public
pri
sourc
vate
institut
india
brazil
china
korea
mexico
negoti
progress
institut
brazil
china
india
egypt
south
africa
facilit
interinstitut
intern
product
develop
see
tabl
exampl
ott
licens
vaccin
conjug
technolog
path
develop
conjug
meningococc
vaccin
collabor
world
health
organ
serum
institut
india
manufactur
vaccin
eventu
distribut
subsaharan
africa
middl
east
latin
america
caribbean
eastern
europ
anoth
licens
agreement
involv
transfer
nih
materi
develop
conjug
vaccin
typhoid
fever
intern
vaccin
institut
ivi
seoul
korea
plan
sublicens
manufactur
public
privat
entiti
indonesia
india
distribut
product
asia
case
ott
adopt
multiprong
strategi
licens
technolog
differ
licens
type
multipl
institut
differ
countri
exampl
nih
ott
licens
technolog
relat
develop
humanbovin
recombin
vaccin
sever
public
privat
institut
brazil
china
india
us
feder
regist
b
depend
countri
geograph
region
licens
exclus
coexclus
nonexclus
degre
exclus
determin
need
prospect
license
countri
grant
exclus
right
need
spur
commerci
segment
world
market
strategi
allow
market
drive
degre
exclus
thu
increas
likelihood
technolog
develop
worldwid
distribut
case
effect
humanbovin
vaccin
goal
import
would
significantli
reduc
childhood
death
relat
infect
develop
countri
nih
ott
found
intern
technolog
transfer
requir
holist
flexibl
approach
donorrecipi
paradigm
eschew
unequ
partnership
consequ
challeng
trust
commit
reliabl
local
scientist
manag
directli
particip
negoti
nih
ott
pursu
agreement
flexibl
determin
hope
strategi
enhanc
tt
emerg
market
ultim
provid
regionalmultilater
philanthrop
organ
option
distribut
product
lower
cost
lesserdevelop
countri
nih
ott
interact
institut
develop
countri
matur
expand
next
step
may
includ
evalu
studi
explor
need
opportun
relat
technolog
transfer
train
lessdevelop
countri
institut
evalu
would
explor
area
impact
biotechnolog
transfer
outcom
ip
polici
regul
clinic
trial
capac
intellectu
properti
manag
ipm
capabl
legisl
influenc
publicpriv
sector
partnership
ppp
thu
ott
potenti
contribut
scientif
techno
logic
health
need
develop
countri
enhanc
abil
bring
market
technolog
benefit
local
region
public
health
institut
provid
guidanc
ipm
andor
organ
train
cours
workshop
address
import
primari
need
associ
health
r
ott
maintain
ongo
dialogu
alreadi
partner
differ
stakehold
area
includ
intern
organ
region
agenc
privat
foundat
profession
societi
moreov
ott
also
initi
intern
capac
build
program
train
scientist
manag
develop
countri
differ
area
technolog
transfer
program
first
phase
includ
staff
visit
china
brazil
india
nih
ott
seek
expand
program
relev
personnel
institut
r
capabl
africa
latin
america
asia
eastern
europ
import
recogn
even
though
biotechnolog
panacea
underdevelop
region
view
import
tool
total
solut
toward
allevi
global
health
dispar
improv
r
ipm
capabl
institut
develop
countri
increasingli
abl
interact
implement
partnership
wide
rang
local
intern
organ
ensur
invent
move
laboratori
patient
ott
continu
forg
new
path
conceiv
intern
biotechnolog
transfer
import
compon
achiev
global
r
goal
nih
ott
commit
contribut
expertis
share
idea
strategi
practic
organ
develop
industri
nation
addit
ott
continu
mutual
learn
partner
altern
creativ
solut
challeng
involv
research
develop
health
technolog
build
strong
track
record
nih
ott
enhanc
licens
biotechnolog
institut
develop
countri
continu
work
stakehold
help
build
technolog
transfer
infrastructur
activ
help
nih
meet
import
part
global
public
health
mission
reduc
devast
diseas
burden
peopl
live
develop
countri
bring
biomed
invent
popul
lessdevelop
region
world
achiev
variou
technolog
licens
model
fit
specif
compet
research
develop
infrastructur
develop
countri
moreov
expect
ott
activ
global
technolog
transfer
promot
good
licens
practic
meet
region
nation
health
prioriti
standard
result
activ
enhanc
public
avail
new
technolog
attract
new
biotechnolog
r
resourc
obtain
return
public
invest
stimul
econom
social
develop
